ALSO NOTED: Genentech selling senior notes; Hi-tech buys Zostrix rights; Corixa shareholders approve takeover; and much more...

> Genentech is offering $2 billion in senior notes to upgrade facilities, fund R&D and for other purposes. Story

> Hi-Tech Pharmacal of Amityville, New York, has acquired the US rights to the brands Zostrix and Zostrix HP, topical analgesic creams from Rodlen Laboratories. Release

> Seattle-based Corixa announced that its shareholders have approved a takeover by GlaxoSmithKline. Story

> Vitae Pharmaceuticals has secured $15 million in financing. Release

And Finally... In the first survey of its kind, researchers found that at least 12,000 Pennsylvanians contracted a hospital infection, costing an extra $2 billion in care and leading to 1,500 preventable deaths. Article

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.